Patient-Centered Outcomes Research Institute Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Washington DC Washington DC United States (2010)

Organization Overview

First Clinical Trial
2017
NCT03345940
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Patient-Centered Outcomes Research Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agoraphobia (Phase 4)

Anxiety Disorders (Phase 4)

Bronchitis (Phase 3)

Bronchitis, Chronic (Phase 3)

Disease (Phase 4)

Fatigue (Phase 4)

Fractures, Bone (Phase 3)

Hip Fractures (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Panic Disorder (Phase 4)

Phobia, Social (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Sclerosis (Phase 4)

Sleep Initiation and Maintenance Disorders (Phase 4)

Surgical Wound Infection (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 17